Hot pepper nose spray relieves hay fever

	Tweet

A second-generation all-natural nose spray called Sinol-M, whose main ingredient is capsaicin derived from hot peppers, safely and effectively relieves stubborn nasal allergies, according to results of a clinical study.

“This study proved for the first time that a homeopathic nasal spray containing capsaicin is an effective treatment for allergic rhinitis,” Dr. Christos Efessiou, CEO of Strategic BioSciences, told Reuters Health.

“Unlike the prescription nasal steroid sprays, this is an all-natural product that has now been demonstrated to provide clinical benefit and is available without a prescription,” principal investigator Dr. Martha White of the Institute for Asthma and Allergy in Wheaton, Maryland, added in a written statement. 

The study findings were presented at the 47th annual meeting of the Western Society of Allergy, Asthma and Immunology in Maui, Hawaii.

Sinol-M differs from its predecessor Sinol, which is a registered homeopathic product in the US. Sinol-M has a patented “mucoadhesive” solution that stays in the nose longer, curbing the frequency of needed doses and diminishes the “hot pepper” sting associated with capsaicin, the study team notes.

In their study, the research team gave Sinol or Sinol-M to 24 people aged 13 and older who suffered from persistent allergic rhinitis (better known as hay fever) to use for a week. They were instructed to use one spray in each nostril as needed up to 12 times a day for the1 week. After a week-long “washout” period, they crossed over the other formulation.

The patients recorded the severity of their runny nose, itchy nose, stuffy nose and sneezing while on the different products. Both Sinol and Sinol-M significantly reduced all nasal allergy symptoms, compared to the pre-treatment and washout periods, the team reports.

However, hay fever symptom relief was achieved with fewer sprays of Sinol-M than Sinol—particularly at night, the researchers found. As expected, Sinol-M also produced less burning sensations in the nose.

Sinol-M is expected to be available in the US beginning in March.

The study was supported by a research grant from Strategic BioSciences, the District of Columbia-based company that has licensed its patented mucoadhesive technology to Sinol USA for the development of Sinol-M.

By Megan Rauscher
NEW YORK (Reuters Health)

RELATED STORIES:
Drug allergy discovery   Kids on cow farms may have fewer allergies   Researchers identify new regulator in allergic diseases   Low serum adiponectin levels predict future risk for asthma in women   Test to improve peanut allergy diagnosis   Anti-IgE Drug Speeds Up Allergy Therapy   Moms Mistakenly Claim Own Food Allergies   Food Allergy Common in Joint Disorder   Molecule That Offers Hope For Future Allergy Treatments Discovered   Adding Proton Pump Inhibitor to Treat Poorly Controlled Asthma in Children Does Not Improve Symptoms   Accelerated infant growth increases risk of future asthma symptoms in children   Getting a Cat Ups Allergy Risk in Adults

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]